GL, EJ, and CG were the principal investigators of the ELAM02, CBF-2006, and ALFA-1200 trials, respectively. NB, SDB, EL, CR, MS, PS, EJ, MB, GL, and AP enrolled patients in the different studies. HL created and handled the patient database. CT, IL and WC reviewed cytogenetic data. LF, ND, AM-R, and PC-L performed genomic analyses. LV and LF assembled and analyzed the data, and drafted the manuscript. JL supervised statistical analyses. LF, NB, and CP supervised the study. All authors revised the manuscript and accepted its final version.
Trending
- PD-L1 expression and survival in unresectable/recurrent gastric cancer treated by 1st-line treatment without immune checkpoint inhibitors: JCOG1013A1
- Managing High-Risk BCLC-C HCC in a Younger Fit Patient
- CELMoD Potency and Cereblon-Mediated Activity in Multiple Myeloma
- <![CDATA[Conclusions and Award Ceremony]]>
- Mixed T-cell chimerism at 3 months predicts late relapse in acute myeloid leukemia after allogeneic stem cell transplantation
- FDA Approves Camizestrant for ESR1-Mutated HR+/HER2– Advanced Breast Cancer
- AI’s Evolving Role in Radiation Oncology
- Alcohol-related cancer deaths in US have more than doubled over three decades | Alcohol

